To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Specifications
- Antibody type:Primary
- Antigen name:Leucine-rich Repeat kinase 2
- Clonality:Polyclonal
- Host:Sheep
- Isotype:IgG
- Reactivity:Human
- Antigen symbol:LRRK2
- Conjugation:Unconjugated
- ImmunoChemistry:Yes
- Size:100 µL
- Epitope:aa 946-962 of Human LRRK2
- Cross adsorption:No
- Format:Lyophilized
- Antigen synonyms:Dardarin|LRRK 2|BC 300-268|PARK8|ROCO2|LRR kinase 2|Leucine-rich repeat kinase 2|LRRK-2
- Immunogen:A synthetic peptide (LKRKRKILSSDDSLRSS; aa 946-962) as part of human LRRK2 protein conjugated to the Blue Carrier Protein has been used as the immunogen.
- Cat. no.:10782-672
- Supplier No.:S-070-100
Specifications
About this item
LRRK2 is a member of the leucine-rich repeat kinase family. It role is yet unknown but it may play a role in the phoshorylation of proteins central to parkinson diseases. LRRK2 contains an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain and a WD40 domain. LRRK2 is present in the cytoplasm but also associates with the mitochondrial outer membrane. Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8). Parkinson disease is characterised by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.
Specificity for LRRK2 has been confirmed by IHC.
Application Information:
IHC. A dilution range of 1:500-1:10000 is recommended. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Type: Primary
Antigen: LRRK2
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope: aa 946-962 of Human LRRK2
Host: Sheep
Isotype: IgG
Reactivity: Human